Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unm...
Task 3.1
Identification of lead nanobodies targeting CD8β, CD69 & CD163...
Description
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- Roche (Switzerland)Switzerlandhttp://www.roche.ch/en/index.htm
- Pfizer (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.pfizer.co.uk/
- Takeda (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.takedacam.com/
- University Medical Center Groningen (UMCG)Netherlands (the)https://www.umcg.nl
- Vrije Universiteit Brussel (VUB)Belgiumhttp://www.vub.ac.be/en/
- University of Münster (UM)Germanyhttps://www.uni-muenster.de
Additional organisations
- Antaros Medical (Sweden)Swedenhttps://antarosmedical.com/
- Bayer (Germany)Germanyhttp://www.gesundheit.bayer.de/de/index.php
- Vall d'Hebron Institute of Oncology (VHIO; VHIO-CERCA)Spainhttps://www.vhio.net
Data originator, Data holder, Data provider
- ImaginAb (United States)United States of America (the)https://www.imaginab.com/
- Janssen (Belgium)Belgiumhttps://www.janssen.com/belgium/
- LygatureNetherlands (the)https://www.lygature.org/
- Amsterdam UMC Location Vrije Universiteit Amsterdam (VUMC)Netherlands (the)https://vumc.nl
- University of CambridgeUnited Kingdom of Great Britain and Northern Ireland (the)https://www.cam.ac.uk
- Vall d'Hebron Institut de Recerca (VHIR; VHIR-CERCA)Spainhttps://vhir.vallhebron.com
Networks
Part of networks...